Dysport™

Dysport (abobotulinumtoxinA), pronounced DIS-port.

The active substance in Dysport is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle. Dysport is a neuromuscular blocking toxin which acts to block acetylcholine release at motor nerve ends and reduces muscular spasm.

Used in patient care in the United Kingdom since 1991, Dysport has marketing authorizations in 76 countries for therapeutic use and in 27 countries for aesthetic use.

Patient exposure is estimated to be above two million single treatment cycles, representing more than 600,000 patients year of treatment.

Dysport was initially developed and subsequently approved in many markets around the world, outside the U.S., for the treatment of movement disorders such as cervical dystonia (spasmodic torticollis), blepharospasm (involuntary eye closure), hemifacial spasm and various forms of muscle spasticity, including post-stroke arm spasticity, spasticity of the lower limbs (calf) in adults and children with cerebral palsy. It was later developed for the treatment of a wide variety of neuromuscular disorders and aesthetic medicine.

Click here for Dysport™ Full Prescribing Information and Patient Medication Guide.

It is possible to read the FDA approval letters.

The Full Prescribing Information and Patient Medication Guide will be available at www.fda.gov.